MDGS - Medigus Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.3000
-0.1300 (-5.35%)
At close: 3:43PM EDT
Stock chart is not supported by your current browser
Previous Close2.4300
Open2.4200
Bid2.2100 x 1300
Ask2.4500 x 800
Day's Range2.2500 - 2.4650
52 Week Range2.1100 - 10.2000
Volume20,482
Avg. Volume20,325
Market Cap8.589M
Beta (3Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-3.2000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Medigus to Invest $5 Million in Algomizer Group

    Medigus Ltd. (MDGS) (MDGS.TA), a technology company developing minimally invasive tools and an innovator in direct visualization technology, announced today the signing of a definitive agreement with Algomizer Ltd. (ALMO.TA) and its wholly-owned subsidiary Linkury Ltd. for an investment of approximately $5 million in Algomizer group. The investment is subject to certain pre-conditions to be met no later than September 30, 2019, including the approval of Medigus’ shareholders for an increase of the authorized share capital of Medigus, and other approvals of Algomizer’s shareholders and creditors.

  • GlobeNewswire20 days ago

    Medigus Reports $1.1 Million Order Backlog for Its Micro-Camera Business

    OMER, Israel, June 06, 2019 (GLOBE NEWSWIRE) --  Medigus Ltd. (MDGS) (MDGS.TA), a pioneer developer of minimally invasive endo-surgical tools and an innovator in direct visualization technology, today announces an order backlog of $1.1 Million as of May 31, 2019 for its micro-camera business. "Our impressive backlog is a testimony to the growth the company experiences. The company's products are becoming more attractive and relevant for a wider range of customers and industries, beyond the medical field.

  • GlobeNewswire23 days ago

    Medigus Signs a Licensing and Sale Agreement for the MUSE™ in Greater China for $3 Million

    Medigus Ltd. (MDGS) (MDGS.TA), a pioneer developer of minimally invasive endo-surgical tools and an innovator in direct visualization technology, today announced the signing of a $3,000,000 agreement with Golden Grand for the know-how licensing and sale of goods for Medigus Ultrasonic Surgical Endostapler (MUSE™) system in China, Hong Kong, Taiwan and Macao. Golden Grand (Shanghai Golden Grand-Medical Instruments Ltd.) has been Medigus’s distributor of the Ultrasonic Surgical Endostapler (MUSE™) systems in China since 2015. Under the terms of the agreement, for the license, training services and goods sold, Golden Grand will pay Medigus the consideration in four installments until the assembly of a production line in China is completed.

  • GlobeNewswire2 months ago

    Medigus Received European Patent Notice Allowance for ScoutCam Irrigation System Technology

    Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today that it has received a notice for patent allowance from the European Patent for its innovative ScoutCam irrigation system. The European patent application number is 13767441.2 and it is titled INTEGRATED ENDOSCOPE IRRIGATION. This technology enables reducing the endoscope's diameter.

  • GlobeNewswire3 months ago

    Medigus Completes patient enrollment of its First Multi-Center MUSE™ Clinical Study in China as Part of the CFDA Clearance Process

    Medigus Ltd. (MDGS) (MDGS.TA), a pioneer developer  of minimally invasive endo-surgical tools and an innovator in direct visualization technology, today announced that patient enrollment of the first multi-center MUSE™ clinical study in China was completed. The study is conducted as part of the process that is required to get clearance for marketing of the MUSE™ System in China by the China Food and Drug Administration, or CFDA. Approval to start the multi-center MUSE™ clinical study was received after the CFDA reviewed the ethics committees' approval and agreements were in place with each center.

  • GlobeNewswire3 months ago

    Medigus Announces the Appointment of Liron Carmel as Chief Executive Officer

    Medigus Ltd. (MDGS) (MDGS.TA) announced the appointment of Liron Carmel as the Company's new Chief Executive Officer effective April 1, 2019. Mr. Carmel has vast experience in business and leadership across multiple industries, including bio pharma, internet technology, oil & gas exploration & production, real estate and financial services. Medigus is the second public company that Mr. Carmel will lead as its Chief Executive Officer.

  • GlobeNewswire3 months ago

    Medigus Files Annual Report on Form 20-F for the Year Ended December 31, 2018

    Medigus Ltd. (“Medigus” or the “Company”) (MDGS) (MDGS.TA), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today that the Company’s annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2018 was filed with the Securities and Exchange Commission on March 28, 2019. The report is available through the Securities and Exchange Commission’s website (www.sec.gov) as well as via the Medigus website (www.medigus.com). Shareholders may receive a hard copy of the annual report free of charge upon request to the Company.

  • GlobeNewswire3 months ago

    Medigus in Negotiations after Execution of Letter of Intent to Invest $5 Million in Algomizer Group

    Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today that it has provided Algomizer Ltd. (ALMO.TA) with a letter of intent for an investment of an aggregate of approximately $5 million in Algomizer group. As part of the investment, Medigus offered to invest NIS 5.4 million directly in Algomizer Ltd., which is engaged in field of internet advertising and whose shares are traded on the Tel Aviv Stock Exchange Ltd. The investment will be made at a price per Algomizer share of NIS 4.15.

  • GlobeNewswire4 months ago

    Medigus to Establish with Linkury an E-Commerce Platform for CBD Products

    OMER, Israel, March 04, 2019 (GLOBE NEWSWIRE) --  Medigus Ltd. (MDGS) (MDGS), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today that it has entered into a binding memorandum of understanding with Linkury Ltd., a leading company in the field of online advertising, which is wholly owned by Algomizer Ltd. (TASE:ALMO). As part of the memorandum of understanding Linkury will establish a commercial technological platform for the manufacturing, marketing and distribution of cannabidiol based (CBD) products. Both Algomizer and Linkury specialize in Internet marketing, with annual sales of approximately NIS 160 million for 2018.

  • Benzinga4 months ago

    Medigus Considers Expanding Portfolio To The Field Of CBD, Medical Marijuana Outside The US

    Shares of Medigus Ltd. (NASDAQ: MDGS ), an Israel-based medical device company that focuses on developing minimally invasive endo-surgical tools, gained more than 11 percent early Thursday morning after ...

  • GlobeNewswire4 months ago

    Medigus Announces Preliminary Interest in the CBD and Medical Cannabis Industry

    Further to the company’s previous reports, the company’s management and board of directors continue to decrease inefficiencies, expand the company’s revenue streams and pursue diversification of its activity portfolio.

  • GlobeNewswire4 months ago

    Medigus Announces US Patent for Micro ScoutCam™ Micro-Visual Technology

    Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today that it has received a patent from the US Patent for its innovative ScoutCam™ Micro-Visual Technology. The U.S patent number is 10,188,275 and it is titled Small Diameter Video Camera Heads and Visualization Probes and Medical Devices Containing Them. The patent refers to small diameter camera heads and small diameter visualization probes with a maximal diameter of 4mm, and small diameter medical devices containing visualization means with a maximal diameter of 4mm.

  • PR Newswire5 months ago

    Medigus to Participate in a European Consortium for the Development of a Fluorescent Colonoscope Intended to Improve Detection of Colorectal Cancer

    Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, announced today that it has filed an application under the framework of a consortium for a European grant for the development of a fluorescent colonoscope from Horizon 2020 fund. The expected duration of the project is four years, and its budget is 3,000,000 Euros and its intention is to improve the ability of early detection of colorectal cancer. In addition to Medigus, three universities from Germany and the Netherlands (Helmholtz Zentrum München, Technical University of Munich, University Medical Center Groningen) and a German company (Amcure), are parties to the consortium.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...

  • GlobeNewswire5 months ago

    Medigus Announces CEO Chris Rowland to Step Down

    OMER, Israel, Jan. 10, 2019 (GLOBE NEWSWIRE) -- (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, announced today that Mr. Chris Rowland, the company’s chief executive officer, will step down effective as of February 28, 2019. Following such date, Mr. Rowland will continue to work with the company as a consultant to contribute from his experience and understanding of the company’s products to promoting shareholder value through the MUSE™ and ScoutCam™ portfolios. Chris Rowland was appointed chief executive officer of Medigus in October 2013 and has since played a key role in the development and commercialization of the Company’s products.

  • GlobeNewswire6 months ago

    Medigus in Advanced Negotiations to License its MUSE™ Technology

    Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that it is in advanced negotiations to grant a license or licenses to its MUSE™ technology Globally and/or in greater China. For this purpose, Medigus commenced advanced talks with relevant multi-national medical device companies and is expected to receive upfront payments that may add up to millions of U.S. dollars should such transactions close.

  • GlobeNewswire7 months ago

    NASA Deploys Medigus’ micro ScoutCam™ Miniature HD Camera During Robotic Refueling Mission

    Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the National Aeronautics and Space Administration (NASA), has incorporated Medigus’ micro ScoutCam™ 8.0 HD, the world’s smallest HD camera and illumination solution, into its Visual Inspection Poseable Invertebrate Robot 2 (VIPIR2).  VIPIR2, a robotic, multi-capability inspection tool being used as part of NASA’s Robotic Refueling Mission 3 (RRM3), was launched into space on December 5, 2018.

  • GlobeNewswire7 months ago

    Medigus Announces Third Quarter 2018 Financial Results

    Medigus Ltd. (“Medigus” or the “Company”) (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and direct visualization technology, today announced financial results for the third quarter ended September 30, 2018. “Following our third quarter results we look forward to future milestones for Medigus to increase the Company’s core business and create shareholder value. In August 2018, the Company announced distribution agreement with Micro-Tech Endoscopy USA, representing a significant milestone for Medigus in the US market.

  • ACCESSWIRE7 months ago

    New Healthcare Trends Have Investors Looking at 4 Stocks

    Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.

  • GlobeNewswire7 months ago

    Medigus Will Form a Separate Company for Its Novel Miniature Video Cameras, Focused on Marketing for New Industries

    Medigus Ltd. (“Medigus” or the “Company”) (MDGS) (MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, announced today that the board of directors of the Company has resolved on a reorganization of the Company, which will include the transfer of all of the Company’s assets and intellectual property related to the Company’s miniature video cameras into a fully owned subsidiary of the Company. This technology transfer is intended to distinguish the Company’s miniature video cameras business from the other operations of the Company and will enable the Company to form a separate business unit with dedicated resources focused on the promotion of this technology.

  • GlobeNewswire7 months ago

    Medigus Board of Directors Announces Cost Reduction Measures

    In the letter, the board of directors of the Company notified the shareholders that further to the review of the company, its financial condition, products and employees, the board of directors of the company has resolved to take steps to reduce the ordinary course expenses of the company by approximately 20% in order to be better aligned with the company’s business needs. The board of directors believes that such steps are required in order to ensure that the company’s resources are used in the most efficient and optimal way to promote the company’s operations.